TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03237312

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic ovarian drilling
Description: The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Antimullerian hormone
Description: 1. In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~2. In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed.
Study: NCT03072082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: One tablet two times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: One tablet two times daily.
Study: NCT01314911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
Study: NCT03911310

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-11
Description: \[18F\]PSMA-11 PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: [18F]PSMA-11
Description: \[18F\]PSMA-11 PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA-11
Description: \[68Ga\]PSMA-11 PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: [68Ga]PSMA-11
Description: \[68Ga\]PSMA-11 PET/CT
Study: NCT02234856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hysterectomy trainer
Description: In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
Study: NCT00479895

Intervention type: DRUG
Group type: OTHER
Intervention: Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
Description: Pre-oxygenated HBOC-201

Intervention type: DRUG
Group type: OTHER
Intervention: Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
Description: Pre-oxygenated HBOC-201
Study: NCT03998813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Locoregional analgesia by femoral triangle catheterization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Tissue infiltration
Study: NCT02824172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cast immobilization group
Description: Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complete sport rest.
Description: Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
Study: NCT03914846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound with elastography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound with elastography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound with elastography
Study: NCT03237312

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Antimullerian hormone
Description: 1. In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~2. In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed.
Study: NCT04386915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG141 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG141 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG141 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG141 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
Study: NCT01798823

Intervention type: PROCEDURE
Intervention: History, physical, LF, SPT, blood sample, FeNO, EBC.
Description: Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.

Intervention type: PROCEDURE
Intervention: History, physical, LF, SPT, blood sample, FeNO, EBC.
Description: Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.

Intervention type: PROCEDURE
Intervention: History, physical, LF, SPT, blood sample, FeNO, EBC.
Description: Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.

Intervention type: PROCEDURE
Intervention: History, physical, LF, SPT, blood sample, FeNO, EBC.
Description: Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
Study: NCT04589286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pack Health's Digital Life Coaching (DLC)
Description: Pack Health smartphone-based DLC platform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Handouts
Description: Generic wellness-related electronic handouts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Handouts
Description: Generic wellness-related electronic handouts
Study: NCT03904095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Psoas Compartment Block Group (GROUP I)
Description: Psoas Compartment Block will perform preoperative to all patients in Group I. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block ( Group II)
Description: ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (GROUP III)
Description: Control group will receive no intervention. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study: NCT04307680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peritron perineometer
Description: Perineometry will be used to assess quality of each observed treatment modality.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peritron perineometer
Description: Perineometry will be used to assess quality of each observed treatment modality.
Study: NCT00182260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton Pump Inhibitors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Nissen Fundoplication
Study: NCT02420353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
Study: NCT04356313

Intervention type: DEVICE
Intervention: GORE® EXCLUDER® Iliac Branch Endoprosthesis
Description: Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component

Intervention type: DEVICE
Intervention: GORE® EXCLUDER® Iliac Branch Endoprosthesis
Description: Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
Study: NCT02957331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study: NCT04275349

Intervention type: DRUG
Intervention: Xingnaojing injection within 24 hours of symptom onset
Description: intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
Study: NCT00624078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
Description: three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
Study: NCT02333968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management support
Description: The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
Study: NCT02234986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: 250 mg oral dose, QD for 28 day cycles
Study: NCT01928576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 300
Study: NCT03072082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg two times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg two times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.
Study: NCT01621958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated perturbation training
Description: One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimal perturbation training
Description: One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
Study: NCT00737061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adiana Transcervical Sterilization System
Description: Implantation of silicone matrix in fallopian tubes
Study: NCT03688789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocortisone supplementation
Description: * Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session~* Hydrocortisone supplementation in patients with biological adrenal insufficiency~* scale of quality of life estimated by EORTC QLQ-C30
Study: NCT04149262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid
Description: Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid
Description: Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 640G pump
Description: MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 640G pump
Description: MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
Study: NCT00610675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 50081
Description: One tablet daily
Study: NCT04126473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: CFTR potentiator
Study: NCT00933062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: 2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
Study: NCT01943279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Follow-up (RFU)
Description: Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-up (SFU)
Description: Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
Study: NCT01546220

Intervention type: OTHER
Group type: OTHER
Intervention: Water colonoscopy
Description: Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
Study: NCT03671083

Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.

Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
Study: NCT02117050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
Study: NCT03849560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grippol® Quadri
Description: Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grippol® Plus, trivalent (Yamagata lineage)
Description: Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grippol® Plus, trivalent (Victoria lineage)
Description: Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
Study: NCT04386915

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.